🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise worldwide, with figures suggesting in excess of 82 million instances per year. Particularly high rates are reported in the African continent and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, escalating drug resistance and the highly restricted available drugs currently available.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Outcomes and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This places it at an comparable level with the typical regimen, which uses two antibiotics. The study involved hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors on the front lines have expressed positive views. The availability of a single-dose, oral treatment of this kind is hailed as a "game-changer" for managing the epidemic. This is viewed as crucial to lessen the impact of the infection for people and to stop the proliferation of extremely resistant gonorrhoea around the world.